13 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 8 Phase 1, 3 Not applicable, 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Not applicable | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Hardness: new trials by email Literature Review of Hardness trials Research Report on Hardness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Subepithelial Connective Tissue Graft as an Autogenous Barrier Membrane for Hard and Soft Tissue Augmentation in Horizontally Deficient Ridges During Delayed Implant Placement Subepithelial Connective Tissue Graft as an Autogenous Barrier Membrane for Hard and Soft Tissue Augmentation in Horizontally Deficient Ridges during delayed implant placement - Horizontally Deficient Alveolar Ridges, Hard and Soft Tissue Augmentation During Delayed Implant Placement | Not applicable | Not yet recruiting | Cairo University | 10 | 2026-10-01 | 2026-10-06 |
| To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard) - Attention Deficit/Hyperactivity Disorder (ADHD) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2025-05-26 | 2025-08-01 |
| Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male Subjects Xetrane® (Pomalidomide) 4 mg Hard Capsule, Imnovid® (Pomalidomide) 4 mg Hard Capsule - Pomalidomide Bioequivalence Study in Healthy Volunteers | Phase 1 | Completed | Knight Therapeutics (USA) Inc | 34 | 2025-01-25 | 2026-07-10 |
| Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device Tiotropium 18 µg inhalation powder, hard capsule, Zephir inhaler - COPD | Phase 1 | Completed | Xiromed LLC | 116 | 2022-10-03 | 2024-02-12 |
| Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Givinostat 10 mg/mL, Midazolam 1mg/ml IV, Midazolam 2.5 mg oromucosal solution - Drug-Drug Interaction, Heathy Volunteer | Phase 1 | Completed | Italfarmaco | 26 | 2022-03-21 | 2025-01-06 |
| Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product Indacaterol/glycopyrronium - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 24 | 2022-02-28 | 2022-07-13 |
| Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler Tiotropium Bromide Monohydrate - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 88 | 2022-02-16 | 2022-08-18 |
| Study to Assess the Efficacy and Safety of Favipiravir-HU Favipiravir HU 200 mg hard capsules, Placebo HU - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 2 | Terminated | University of Pecs | 1 | 2021-11-25 | 2022-11-09 |
| Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects. Dexlansoprazole - Healthy, Bioequivalence Study | Phase 1 | Completed | University of Karachi | 60 | 2021-09-18 | 2023-11-29 |
| A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People LEO 32731 modified release tablet, LEO 32731 blend, hard capsule, LEO 32731 API, hard capsule - Healthy | Phase 1 | Completed | LEO Pharma | 66 | 2019-01-22 | 2019-07-01 |
| Effects of Shoe Cushioning and Body Mass on Injury Risk in Running Hard cushioned running shoes, Soft cushioned running shoes - Running-Related Injury (First-time) | Not applicable | Completed | Luxembourg Institute of Health | 874 | 2017-09-20 | 2019-02-26 |
| A Long-term Safety Study of QVM149 in Japanese Patients With Asthma QVM149 - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 96 | 2017-04-28 | 2020-04-07 |
| Assessment of Dietary Biomarkers and Metabolic Effects After the Intake of Milk and Cheese Cow´s milk (3.9% fat, pasteurized), hard, yellow cheese, Soy based drink - Healthy | Not applicable | Unknown | Centre Hospitalier Universitaire Vaudois | 12 | 2015-08-01 | 2016-03-10 |
| Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD) Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation, Indacterol 300 µg, Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 645 | 2011-11-06 | 2018-07-27 | |
| Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation Oseltamivir - Influenza | Phase 4 | Completed | Pharmahungary Group | 6 | 2010-06-01 | 2012-10-08 |
| Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder), EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules), Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder) - Osteoarthrosis | Phase 3 | Completed | Azidus Brasil | 280 | 2009-10-01 | 2013-02-25 |
Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Attention Deficit Disorder with Hyperactivity (1) · Dyspnea (1) · Influenza, Human (1) · Osteoarthritis (1)
Orion Corporation, Orion Pharma (2) · Azidus Brasil (1) · Boehringer Ingelheim (1) · Cairo University (1) · Centre Hospitalier Universitaire Vaudois (1) · Humanis Saglık Anonim Sirketi (1) · Italfarmaco (1) · Knight Therapeutics (USA) Inc (1) · LEO Pharma (1) · Luxembourg Institute of Health (1) · Novartis Pharmaceuticals (1) · Pharmahungary Group (1) · University of Karachi (1) · University of Pecs (1) · Xiromed LLC (1)
Finland (2) · Hungary (2) · India (2) · Brazil (1) · Chile (1) · Germany (1) · Japan (1) · Luxembourg (1) · Pakistan (1) · Portugal (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Daniel Theisen, PhD (1) · Laurent Malisoux, PhD (1) · Marlene Fonseca, MD (1) · Prof. Dr. Muhammad R Shah, PhD (1)
PMID 28753012, PMID 28827268, PMID 31877062, PMID 32133503, PMID 32781913, PMID 34859204, PMID 35014593, PMID 35049407, PMID 38196940, PMID 41122014, PMID 42515769
2018 (1)